Jerzy TROJAN (Jerzy Leslaw Trojan de Wierblany) has completed Dr d’Etat ès Sci. (HDR) in Sorbonne - P.&M. Curie. He has performed scientific and clinical researches in cancerology principally in French NIH (INSERM, Cancer Center Villejuif/Paris), then CWRU University (School of Medicine) USA, and Colombian NIH (INS) among others. His research results were described in almost 400 publications (145 articles, 102 book chapters, 5 books) - more than 3600 citations. Thanks to his contribution in biomedicine, he was elected the member of prestigious French Academy of Medicine – ANM, Paris 2017. NOVEL CONTRIBUTION TO BIOMEDICAL SCIENCE: 1. Establishment of cancer gene therapy (immuno-gene therapy) as a new oncology domain [Science, 1993; Wikipedia - Gene therapy, 1990s – 2020s; Curr Med Chem, 2024; CNS & ND-DT, 2026]: application – international project of glioblastoma therapy; 2. Demonstration of the convergence existing between neuro-ontogenesis and neuro-oncogenesis using AFP and IGF-I as new biomarkers [Dev Neurosci, 1984; PNAS USA, 1994; AMOR, 2016; FB-E, 2025]: application – chronogram of CNS differentiation. PUBLICATIONS AND CITATIONS: ResearchGate: httsp://www.researchgate.net/profile/Jerzy Trojan/citations/